- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03921359
SMARTfit Training for Parkinson's Disease
July 2, 2020 updated by: Charles Liu, University of Southern California
Effect of SMARTfit Training on Motor, Cognitive Functions and Brain Connectivity in Individuals With Parkinson's Disease: a Pilot Study
This pilot study aims to investigate the effects of 8-week SMARTfit training versus conventional physical training on motor function, cognition and brain functional connectivity in individuals with PD.
The investigators hypothesize that clinical and physical performance will improve after SMARTfit training more than after conventional physical training.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Although Parkinson's disease (PD) has been mainly viewed as a movement disorder, the pathophysiology of declined motor function incorporates impairments of multiple systems, including sensory, motor and cognitive pathways.
Specifically, it has been demonstrated that cognitive function may play an essential role in motor function for individuals with PD.
Cognitive dysfunction involving set-shifting and attentional control has been found to be associated with movement slowness in performing a finger sequence task and freezing of gait.
Furthermore, a recent rodent model indicates that cognitive dysfunction may occur prior to the onset of motor symptoms.
Similarly human studies show that 25-30% individuals with PD exhibit cognitive impairments at the time of diagnosis.
The overall evidence suggests that cognitive dysfunction may contribute to degraded motor function in PD.
Interestingly, several studies demonstrate that aerobic exercise and resistance training can improve cognitive function in individuals with PD, indicating a tight interplay between motor and cognitive function.
Targeting cognitive function by incorporating cognitive training into physical rehabilitation may be important for people with PD.
Although there is mounting evidence for the benefits of physical exercise in PD, few studies investigate whether combining cognitive training with physical exercise can provide additional benefits than physical exercise alone.
Thus, the purpose of this pilot study is to investigate the effect of SMARTfit training, a novel technology that provides an opportunity to combine physical training with cognitive training, in individuals with PD.
The hypothesis is that SMARTfit training will promote greater motor and cognition improvements than conventional physical training.
To test the above hypothesis, ten individuals with mild PD will receive both SMARTfit training and conventional physical training in a counterbalanced order with a washout period.
For each training program, participants will receive a 1-hour training session 3 times per week for 8 weeks.
The changes in disease biomarkers before and after training will also be explored.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC Center for Neurorestoration
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 50-85 years of age
- Diagnosis of idiopathic Parkinson's disease using the UK Brain Bank criteria (as determined by the study movement disorders neurologist) with Hoehn and Yahr stage 1-2
- No contraindications to exercise including untreated cardiovascular disease or stroke
- Medically stable and optimized on their medications
- Able to ambulate independently with or without device
- No other neurologic, neuromuscular, or orthopedic disease
- No serious cognitive deficits and able to participate in the informed consent process
- With medical clearance from primary care physician to participate in the physical therapy intervention
- No contraindications for MRI
Exclusion Criteria:
- Severe cardiac disease (New York Heart Association classification II-IV)
- Systolic blood pressure reduction of greater than 20 mmHg with standing
- A history of poorly controlled or brittle diabetes
- A history of lower limb amputation
- Been prescribed any new dopamine replacement medications or new mood stabilizer medications.
- Presence of a lower limb non-healing ulcer
- Montreal cognitive assessment score of less than 21
- The presence of any medical condition which the investigator believes might present an unacceptable health risk to the subject should they participate in the study
- Electrically, magnetically, or mechanically activated implant (such as cardiac pacemakers or intracerebral vascular clip)
- Metal in any part of the body including metal injury to the eye
- History of brain lesions (such as stroke), seizures, or unexplained spells of loss of consciousness
- Pregnant or breast-feeding
- With other neurologic, neuromuscular, or orthopedic disease that would interfere with ability to participate in exercise training
- Currently participating in other studies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Conventional physical training
Participants assigned to this arm will receive the conventional physical training.
|
For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks.
During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with.
The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing.
Participants will focus on practicing one pair of tasks during each session.
There is an additional cognition component that can be manipulated using features provided by SMARTfit.
For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks.
During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with.
The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing.
Participants will focus on practicing one pair of tasks during each session.
|
Experimental: SMARTfit training
Participants assigned to this arm will receive the SMARTfit training.
|
For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks.
During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with.
The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing.
Participants will focus on practicing one pair of tasks during each session.
There is an additional cognition component that can be manipulated using features provided by SMARTfit.
For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks.
During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with.
The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing.
Participants will focus on practicing one pair of tasks during each session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-post training change in Modified Physical Performance Test score (mPPT)
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
The mPPT is a 9-item test that assesses multiple dimensions of physical function (basic and complex activities of daily living) with different levels of difficulty.
Participants will be asked to complete functional tasks (i.e.
writing a sentence, simulated eating, lift a book and put it on a shelf, turning 360 degrees, 50-foot walking test, stair climbing etc.).
Total score ranges from 0 to 36, with a higher score indicating better physical function.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-post training change in MDS-UPDRS score
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
The UPDRS is an assessment of Parkinson's disease severity and progress.
The UPDRS has four sections.
The first section assesses mental, mood, and behavioral changes.
The second section assesses historical activities of daily living.
The third section is the motor examination portion of the UPDRS and includes evaluations of tremor, rigidity, bradykinesia, gait, and postural instability.
The fourth section evaluates complications of therapy including motor fluctuations and dyskinesias.
Total score ranges from 0 to 260, with a higher score indicating greater disease severity.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Pre-post training change in Self-Efficacy for Exercise scale (SEES)
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
The SEE is to capture an individual's confidence in their ability to continue exercising in the face of barriers to exercise.
The SEE consists of 9 items describing potential barriers to participation in exercise (e.g., "too busy with other activities," "did not enjoy exercise," "felt pain with exercise," "bored by the exercise").
For each item, participants circled a number from 0 ("not confident") to 10 ("very confident") that best described their belief that they could exercise 3 times a week for 20 minutes.
Total score ranges from 0 to 90, with a higher score indicating higher self-efficacy for exercise.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Pre-post training change in trail-making test (TMT)
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
The Trail Making Test is a neuropsychological test of visual attention and task switching.
It consists of two parts in which the participant is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.
The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Pre-post training change in Parkinson's Disease-Cognitive Rating Scale (PDCRS)
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
The PDCRS is is a valid, reliable and useful neuropsychological battery designed to cover the full spectrum of cognitive defects associated with PD.
The PDCRS includes 10 'subcortical-type' items (attention, working memory, Stroop test, four verbal fluencies, immediate and delayed verbal memory, clock drawing), and two 'cortical-type' items (naming, copy of a clock).
Total score ranges from 0 to 204, subcortical score from 0 to 174, and cortical score from 0 to 30, with higher scores indicating a better functioning.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Pre-post training change in Quotient system test
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
The Quotient test is an innovative device that objectively measures three domains of cognition: hyperactivity, inattention and impulsivity.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Pre-post training change in functional connectivity
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Participants will receive resting state fMRI, in which they will be instructed to keep their eyes open fixation on a projected image of a white cross on a black background.
Participants will also receive task-based fMRI, in which they will be asked to perform a word-color Stroop task.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Pre-post training change in EEG delta (2.5-4 Hz) bandpower
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
A 19-channel EEG acquisition system will be used in recording.
Participants will be instructed to sit quietly with eyes closed whilst wearing a skull cap.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Change in the concentration of α-synuclein and DJ-1
Time Frame: pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
A venous blood sample of up to 40 ml will be obtained from participants.
|
pre-assessment 1 (baseline), post-assessment 1 (8 weeks), pre-assessment 2 (after 2-month washout period after post-assessment 1, 16 weeks), post-assessment 2 (24 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 19, 2018
Primary Completion (Actual)
February 2, 2020
Study Completion (Actual)
March 16, 2020
Study Registration Dates
First Submitted
January 8, 2019
First Submitted That Met QC Criteria
April 16, 2019
First Posted (Actual)
April 19, 2019
Study Record Updates
Last Update Posted (Actual)
July 7, 2020
Last Update Submitted That Met QC Criteria
July 2, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-17-00928
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on SMARTfit training
-
State University of New York at BuffaloCompleted
-
University of Trás-os-Montes and Alto DouroCompletedLipid Metabolism Disorders | Sarcopenia | Osteoporosis | Overweight and Obesity | Personal Satisfaction | Hypertension With Complications and Secondary HypertensionPortugal
-
New Jersey Institute of TechnologyRutgers, The State University of New JerseyCompletedHemiplegia | Hemiparesis | Cerebrovascular AccidentUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedHypertension | Diabetes | Peripheral Arterial DiseaseBrazil
-
Riphah International UniversityRecruiting
-
Lebanese UniversityCompletedHeart Failure | Quality of Life | Cardiac Rehabilitation | Aerobic Exercise | Exercise Intolerance | Respiratory Muscle Training | Strength Training
-
Poznan University of Physical EducationPoznan University of Medical Sciences; National Science Centre, PolandActive, not recruitingHealthy Athletes Aged 18-35 YearsPoland
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedHyperglycemia | Diabetes Mellitus, Type 2Norway